Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
Stephen Chan(Heidelberg University), P. Fumoleau(Institut Curie), Aňa Lluch(Hospital Clínico Universitario de Valencia), Gilles Romieu(Institut de Cancérologie de l'Ouest), Bente Frimodt‐Moller(Heidelberg University), Antonio Llombart‐Cussac(MedSIR (Spain)), Eva Carrasco(Heidelberg University), R. Kreienberg(Heidelberg University), T. Delozier(Mount Vernon Hospital), Andreas du Bois(Kliniken Essen-Mitte), M Harrison(Heidelberg University), A. Thareau Vaury(Heidelberg University), Jens Huober(University of St.Gallen), Alison Jones(Roche (Switzerland)), Andreas Schneeweiß(German Cancer Research Center), M. Tubiana-Hulin(Heidelberg University), Antonio Antón(Hospital Universitario Miguel Servet), José Mayordomo(Royal Bournemouth Hospital)
Cited by 119
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k